Results 11 to 20 of about 80,637 (252)

Baseline neutrophil-to-eosinophil-ratio and outcome in metastatic clear-cell renal cell carcinoma treated with nivolumab or ipilimumab/nivolumab

Acta Oncologica
Background and purpose: This study aims to evaluate neutrophil-to-eosinophil ratio (NER) as a prognostic and/or predictive biomarker in metastatic clear cell renal cell carcinoma (m-ccRCC) treated with nivolumab or ipilimumab/nivolumab.
Yana Beulque, Lisa Kinget, Eduard Roussel, Sajedeh Mobaraki, Annouschka Laenen, Philip R. Debruyne, Yannick Van Herck, Marcella Baldewijns, Agnieszka Wozniak, Abhishek D. Garg, Jessica Zucman-Rossi, Gabrielle Couchy, Maarten Albersen, Liesbeth De Wever, Lorenz Haaker, Benoit Beuselinck   +15 more
doaj   +5 more sources

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. [PDF]

, 2022
PURPOSE: In the phase III CheckMate 067 trial, durable clinical benefit was demonstrated previously with nivolumab plus ipilimumab and nivolumab alone versus ipilimumab. Here, we report 6.5-year efficacy and safety outcomes.
Dummer, R, Daniels, GA, Ferrucci, PF, Hodi, FS, Bas, T, Ascierto, PA, Schadendorf, D, Ritchings, C, Wolchok, JD, Schöffski, P, Grob, JJ, Wagstaff, J, Cowey, CL, Haanen, JBAG, Hill, A, Long, GV, Lao, CD, Gonzalez, R, Lebbé, C, Rutkowski, P, Smylie, M, Carlino, MS, Guidoboni, M, Larkin, J, Márquez-Rodas, I, Butler, MO, McArthur, G, Grob, J-J, Chiarion-Sileni, V, Maio, M   +29 more
core   +4 more sources

Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.

, 2022
BACKGROUND: Lymphocyte-activation gene 3 (LAG-3) and programmed death 1 (PD-1) are distinct inhibitory immune checkpoints that contribute to T-cell exhaustion.
Abaskharoun, Mena, Rutkowski, Piotr, Srivastava, Shivani, Lao, Christopher D, Long, Georgina V, Gogas, Helen J, Dalle, Stéphane, Hamilton, Melissa, Castillo Gutiérrez, Erika, De Menezes, Juliana Janoski, Arance, Ana, Grob, Jean-Jacques, Lipson, Evan J, Sobiesk, Anne Marie, Li, Bin, Hodi, F Stephen, Tawbi, Hussein A, Keidel, Sarah, Nair, Suresh G., MD, Schadendorf, Dirk, Matamala, Luis, Ascierto, Paolo A, Simonsen, Katy L   +22 more
core   +3 more sources

Nivolumab-Related Dry Mouth and Dry Eye: Cross-Sectional Study

, 2021
To evaluate ICIs related dry eye and dry mouth in nivolumab therapy, 24 patients receiving nivolumab (group 1), 30 patients in remission without treatment for 6 months (group 2), 30 healthy participants (group 3) were cross-sectionally examined. Schirmer’
Kerem Poyraz (11466373), Yunus Guzel (11466382), Halil Kömek (11466388), Hülya Etem (11466385), Cihan Gundogan (11466379), Ozgen Ahmet Yildirim (11466370), Canan Can (5031644), Erkan Erdur (11466376)   +7 more
core   +1 more source

Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients

Therapeutics and Clinical Risk Management, 2019
Shi Zhou,* Samrat Khanal,* Haijun Zhang Department of Oncology, Zhongda Hospital, Medical School of Southeast University, Nanjing, Jiangsu, People’s Republic of China *These authors contributed equally to this work Purpose: The aim of this study
Zhou S, Khanal S, Zhang H
doaj   +1 more source

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238

, 2023
lumab significantly improved recurrence-free survival (RFS) and distant metastasis-free survival versus ipilimumab in patients with resected stage IIIB–C or stage IVmelanoma,with benefit sustained at 4 years.
Gogas, Helen, Arance Fernandez, Ana M., Del Vecchio, Michele, Weber, Jeffrey, Larkin, James, Mandalá, Mario, Dalle, Stéphane, Cruz Merino, Luis de la   +7 more
core   +1 more source

Gut microbiota–derived short‐chain fatty acids regulate group 3 innate lymphoid cells in HCC

Hepatology, EarlyView., 2022
Abstract Background and Aims Type 3 innate lymphoid cells (ILC3s) are essential for host defense against infection and tissue homeostasis. However, their role in the development of HCC has not been adequately confirmed. In this study, we investigated the immunomodulatory role of short‐chain fatty acids (SCFAs) derived from intestinal microbiota in ILC3
Chupeng Hu, Bingqing Xu, Xiaodong Wang, Wen‐Hua Wan, Jinying Lu, Deyuan Kong, Yu Jin, Wenhua You, Hua Sun, Xiaoxin Mu, Dongju Feng, Yun Chen   +11 more
wiley   +1 more source

Genital lichen sclerosus after nivolumab [PDF]

, 2020
We report a patient with metastatic melanoma undergoing treatment with nivolumab who developed genital lichen sclerosus.
Soda, Giuseppe, Miraglia, Emanuele, Giustini, Sandra   +2 more
core   +1 more source

Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis

Hepatology, EarlyView., 2022
Phase 1b study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis. Abstract Background and Aims We evaluated the efficacy and safety of the antiangiogenic tyrosine kinase inhibitor anlotinib plus TQB2450, a programmed death‐ligand 1 inhibitor in pretreated advanced biliary tract cancers (BTCs ...
Jun Zhou, Yongkun Sun, Wen Zhang, Jiajia Yuan, Zhi Peng, Wei Wang, Jifang Gong, Lin Yang, Yanshuo Cao, Hong Zhao, Chao Chen, Weifeng Wang, Lin Shen, Aiping Zhou   +13 more
wiley   +1 more source

Nivolumab cohort

, 2022
clinical course in AEC patients treated with ...
Naoki Takegawa (10148882)
core   +1 more source